Press "Enter" to skip to content

Ophthalmic Drugs Market Size 2019 – Growing Demand Status of Top Manufacturers with Industry Share, Size, Projection, Consumption Forecast to 2024


The “Ophthalmic Drugs Market” report 2019 covers all the significant developments which are recently being adopted across the global market. The prime objective of Ophthalmic Drugs market report is to provides an in-depth analysis of all market dynamics including drivers and restraints, and trends and opportunities. The Ophthalmic Drugs market report covers both the demand and supply aspect of the market. The report also highlighted the future trends in the Ophthalmic Drugs market that will impact the demand during the forecast period.

Scope of the Report:

  • As per the , ophthalmic drugs are the drugs used for treating glaucoma, cataracts, diabetic retinopathy, and other ophthalmic disorders. An increasing prevalence of eye disorders and increasing R&D on the development of novel drugs are the major factors driving growth in the global ophthalmic drugs market. The market is segmented by drug class, product type, and geography.

    Get a Sample Copy of the Report –

    Market Overview:

  • The major factors attributed to the growth of the ophthalmic drugs market include the increasing incidence and prevalence of eye-related disorders, rising R&D activities pertaining to the development of novel drugs, and increasing focus on developing combination therapies.
  • The increasing prevalence of eye diseases is increasing the demand for ophthalmic drugs, globally. In many developed and developing countries, eye conditions have emerged as potential threats to the status of sight of their populations. The increase in the prevalence of diabetes in various countries has caused diabetic retinopathy to be added to the priority list. Glaucoma, an eye disease known for centuries, remains on the public health agenda due to difficulties in its early diagnosis and frequent necessity of life-long treatment. According to the WHO, in 2018, it was estimated that approximately 1.3 billion people were living with some form of vision impairment, 188.5 million people had a mild vision impairment, 217 million had moderate to severe vision impairment, and 36 million people are blind. Globally, the leading causes of vision impairment are uncorrected refractive errors and cataracts, and the majority of people with vision impairment are over the age of 50 years. According to the WHO, chronic eye diseases are the number one cause of vision loss, with the top two causes being unoperated cataracts and uncorrected refractive errors. The former is the leading cause in countries with low- or middle-incomes. More than 80% of the vision impairments are curable or preventable, which means that these drugs are required for the management of the diseases. Hence, the rising incidence of eye-related disorders is projecting a great impact on the growth of market studied.<

    Some of the Top Key Players of Ophthalmic Drugs Market Report Are:

  • Aerie Pharmaceuticals Inc.
  • Allergan
  • Bausch Health Companies Inc.
  • Bayer AG
  • F. Hoffmann
  • La Roche Ltd
  • Hoya Corporation
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Santen Pharmaceutical Co. Ltd

    Report Highlights:

    • Market Dynamics – Drivers, Restraints, and Opportunities
    • Market Segmentation – Types, Applications, Regions, and Technology
    • Market Trends
    • Competitive Landscape
    • SWOT Analysis and Porter’s Five Forces Analysis

    For More Information or Query or Customization Before Buying, Visit at

    Key Market Trends:

    The Dry Eye Segment under Drug Class is Expected to Account for the Largest Market Share during the Forecast Period

    Dry eye disease (DED) is a multi-factorial disease of the tear film and ocular surface that results in ocular discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is a generally under-diagnosed clinical condition, as patients often attribute the experienced DED symptoms to aging, and hence, it remains an under-researched condition in the low- and middle-income countries. The prevalence of DED can be as high as 30% of the total population. In the last decade, only one drug was approved for the treatment of DED by the US Food and Drug Administration (FDA) (i.e., Restasis by Allergan Inc.). DED is a major public health problem, the burden of which is likely to increase due to the increasing proportion of the aging population and the adoption of modern lifestyle. Dry eye disease is a common ocular disorder in the elderly and a frequent cause of eye care visits among this age group. The total annual cost of dry eye drug to the US economy can be more than USD 55 billion. Thus, the development of new drug treatments for dry eye is essential for both the dry eye patients and the ophthalmic industry. Many drugs are in the pipeline for dry eye diseases. The increasing prevalence of DED, approval of drugs for its treatment, and government initiatives to eradicate it are the main factors spurring the growth of the market studied.

    The Asia-Pacific Segment is Expected to Account for the Fastest Growth Rate

    The ophthalmic drugs market is expanding and growing, globally. The market has been witnessing an especially exponential growth in the Asia-Pacific region. Glaucoma and tear substitute (for dry eye) drugs are the leading products in Asia-Pacific. India is likely to be among the top three pharmaceutical markets by incremental growth and the sixth-largest market, globally, in absolute size, according to the Clinical and Experimental Vision and Eye Research, India, 2018. Increase in the number of middle-class households, advancement in medical infrastructure, and the increasing penetration of health insurance in the country are likely to play a significant role in influencing this growth. According to the National Health Policy (NHP), in India, glaucoma is the leading cause of irreversible blindness with at least 12 million people have affected and nearly 1.2 million people having blinded from the disease. More than 90% of the cases of glaucoma remain undiagnosed in the country.

    Moreover, the prevalence of glaucoma increases with age. Thus, the rising prevalence of glaucoma and an increase in healthcare expenditure are spurring the growth of the ophthalmic drugs market in India. Furthermore, the country’s government is also playing an important role, since the cost of glaucoma treatment in India is one of the lowest in the world.

    The Report Covers:

    • Comprehensive research methodology of Ophthalmic Drugs market
    • In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
    • Analysis of regional regulations and other government policies impacting the global sleep aid market
    • Insights about market determinants which are stimulating the global Ophthalmic Drugs market
    • Detailed and extensive market segments with regional distribution of forecasted revenues
    • Extensive profiles and recent developments of market players Companies Mentioned

    Purchase this Report (Price 4250 USD for single user license) –

    Detailed TOC of Ophthalmic Drugs Market Report 2019-2024:

    1.1 Study Deliverables
    1.2 Study Assumptions
    1.3 Scope of the Study



    4.1 Market Overview
    4.2 Market Drivers
    4.2.1 Increasing Incidence and Prevalence of Eye-related Disorders
    4.2.2 Rising R&D Pertaining to the Development of Novel Drugs
    4.2.3 Increasing Focus on Developing Combination Therapies
    4.3 Market Restraints
    4.3.1 Loss of Patent Protection for Popular Drugs
    4.3.2 Lack of Health Insurance in the Developing Countries
    4.4 Porter’s Five Forces Analysis
    4.4.1 Threat of New Entrants
    4.4.2 Bargaining Power of Buyers/Consumers
    4.4.3 Bargaining Power of Suppliers
    4.4.4 Threat of Substitute Products
    4.4.5 Intensity of Competitive Rivalry

    5.1 By Drug Class
    5.1.1 Anti-glaucoma Drug
    5.1.2 Dry eye Drug
    5.1.3 Ophthalmic Anti-allergy/Inflammatory
    5.1.4 Retinal Drug
    5.1.5 Anti-infective Drugs
    5.1.6 Other Drugs
    5.2 By Product Type
    5.2.1 OTC Drug
    5.2.2 Prescription Drug
    5.3 Geography
    5.3.1 North America US Canada Mexico
    5.3.2 Europe Germany UK France Italy Spain Rest of Europe
    5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
    5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
    5.3.5 South America Brazil Argentina Rest of South America

    6.1 Company Profiles
    6.1.1 Aerie Pharmaceuticals Inc.
    6.1.2 Allergan
    6.1.3 Bausch Health Companies Inc.
    6.1.4 Bayer AG
    6.1.5 F. Hoffmann-La Roche Ltd
    6.1.6 Hoya Corporation
    6.1.7 Novartis AG
    6.1.8 Pfizer Inc.
    6.1.9 Regeneron Pharmaceuticals Inc.
    6.1.10 Santen Pharmaceutical Co. Ltd



    Contact Us:

    Name: Ajay More

    Phone: US +14242530807/ UK +44 20 3239 8187

    Email: [email protected]

    Our Other Reports:

    Global Electronic PC Accessories Market 2019: Industry Size & Share, Business Strategies, Growth Analysis, Regional Demand, Revenue, Key Manufacturers and 2024 Forecast Research Report

    Aircraft Cargo System Market Share, Size 2019 | Development Strategy, Size, Share, Future Demands, Sales-Revenue, Growth Factors, Industry Updates and Key Players Analysis till 2024

    Global L-serine Market 2019 Size, Shares, Production, Consumption, Factors Driving, Trends, Challenges

    Automotive Biometric Vehicle Access System Market 2019 Global Trends, Industry Analysis by Size, Share, Segment, Regional Analysis, Growth Statistics Forecast to 2023

  • Be First to Comment

    Leave a Reply

    Your email address will not be published. Required fields are marked *